The interaction between IL-8 and ICI therapy is unclear. However, studies have reported that increased levels of IL-8 are correlated with longer overall survival (OS) in non-small-cell lung cancer (NSCLC) patients treated with nivolumab, and anti-PD-1 ICI [44]. This evidence concerns the gene CXCL8 and non-small cell lung carcinoma.